Table 4 Multivariate analysis for... | American Society of Hematology

Table 4

Multivariate analysis for association of biomarkers with cGVHD

Biomarker	Replication set 1				Replication set 2
Biomarker	Effect size*	P	Other effects†	P	Effect size*	P	Other effects†	P
Aminopeptidase N	1.1×	.41	None		1.2×	.13	Age ≥ 50 y 1.3×	.03
ICAM-1	1.2×	.11	Unrelated donor 0.8×	.02	1.2×	.45	None
CXCL10	1.5×	.04	TBI 1.8×	.04	2.7×	.005	None
			NMA 1.9×	.01
			Mismatch 2.1×	.01
			BM 0.5×	.04
Endothelin-1	1.0×	.89	aGVHD 1.6×	.02	0.7×	.04	TBI 1.8×	.01
			Mismatch 2.0×	.04
			Umbilical cord blood 0.3×	.0005
CXCL9	1.5×	.03	aGVHD 0.6×	.003	1.5×	.29	None
			NMA 2.3×	.001
IL-2Rα	1.2×	.02	Late onset 0.8×	.003	1.0×	.99	None
			TBI 1.3×	.05
			NMA 1.6×	.0001
Anti-LG3	0.9×	.47	aGVHD 0.6×	.0006	0.7×	.28	Female donor to male recipient 0.4×	.01
sBAFF	1.2×	.05	Late onset 0.8×	.04	1.2×	.38	None
			BM 0.7×	.04
			Umbilical cord blood 0.7×	.02
PI-16	0.9×	.46	None		0.6×	.008	None
Gelsolin	1.0×	.35	TBI 0.9×	.03	0.8×	.03	None
			Mismatch 0.9×	.04
Kallikrein	1.0	.51	None		1.1×	.24	BM 1.7×	.02

Biomarker	Replication set 1				Replication set 2
Biomarker	Effect size*	P	Other effects†	P	Effect size*	P	Other effects†	P
Aminopeptidase N	1.1×	.41	None		1.2×	.13	Age ≥ 50 y 1.3×	.03
ICAM-1	1.2×	.11	Unrelated donor 0.8×	.02	1.2×	.45	None
CXCL10	1.5×	.04	TBI 1.8×	.04	2.7×	.005	None
			NMA 1.9×	.01
			Mismatch 2.1×	.01
			BM 0.5×	.04
Endothelin-1	1.0×	.89	aGVHD 1.6×	.02	0.7×	.04	TBI 1.8×	.01
			Mismatch 2.0×	.04
			Umbilical cord blood 0.3×	.0005
CXCL9	1.5×	.03	aGVHD 0.6×	.003	1.5×	.29	None
			NMA 2.3×	.001
IL-2Rα	1.2×	.02	Late onset 0.8×	.003	1.0×	.99	None
			TBI 1.3×	.05
			NMA 1.6×	.0001
Anti-LG3	0.9×	.47	aGVHD 0.6×	.0006	0.7×	.28	Female donor to male recipient 0.4×	.01
sBAFF	1.2×	.05	Late onset 0.8×	.04	1.2×	.38	None
			BM 0.7×	.04
			Umbilical cord blood 0.7×	.02
PI-16	0.9×	.46	None		0.6×	.008	None
Gelsolin	1.0×	.35	TBI 0.9×	.03	0.8×	.03	None
			Mismatch 0.9×	.04
Kallikrein	1.0	.51	None		1.1×	.24	BM 1.7×	.02

Multivariate analysis was adjusted for early vs late onset, prior aGVHD, conditioning (myeloablative, myeloablative with total body irradiation [TBI], nonmyeloablative [NMA]), female donor to male recipient, source (peripheral blood stem cell, bone marrow [BM], umbilical cord blood), donor (matched related, matched unrelated, mismatched [HLA mismatch]), and age 50 years or older. Late onset is defined as cGVHD ≥9 months after BMT.

Fold difference for cGVHD vs control.

†

Other factors in model significant at 0.05 level.

View Large

This Feature Is Available To Subscribers Only